Prevalence of antidepressants and biosimilars in elite sport
Authors:
- 1 June 2009
- journal article
- research article
- Published by Wiley in Drug Testing and Analysis
- Vol. 1 (6) , 286-291
Abstract
The use of prescribed antidepressants by athletes has not been restricted in human sports since 2003, after the antidepressants bupropion and amineptine were removed from the list of prohibited substances. Recent awareness of antidepressants has been stimulated by reports from the media concerning possible misuse of antidepressants among healthy athletes.The prevalence of antidepressants has been monitored over the past ten years with screening procedures routinely used by WADA‐accredited laboratories. The growth in antidepressant use among athletes peaked in 2007 and 2008 after a modest increase over the first eight years of this survey. Pharmacy prescriptions for antidepressants in Germany did not show a correlated growth during this period. The increasing variety of antidepressant medications has led to a continued increase in the diversity of antidepressant substances used by athletes and the ‘normal’ population. The number of different sports affected by the presence of antidepressants has increased in the past decade, especially in endurance sports. The predominance of female antidepressant users in the normal population was reflected in the athletes' group. We concluded from our results that the development of antidepressant prevalence in elite sports did not correlate with that among the general public in Germany. Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 19 references indexed in Scilit:
- Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug AdministrationPLOS Medicine, 2008
- Moderne Antidepressiva: Pharmakokinetik, Interaktionspotenzial und TDMPharmazie in unserer Zeit, 2004
- The Metabolic Fate of Amitriptyline, Nortriptyline and Amitriptylinoxide in ManDrug Metabolism Reviews, 2004
- Role of Neurotrophic Factors in the Etiology and Treatment of Mood DisordersNeuroMolecular Medicine, 2004
- Molecular Mechanism of Citalopram and Cocaine Interactions with Neurotransmitter TransportersThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Preventing Inpatient SuicideThe Journal of Clinical Psychiatry, 2003
- Exercise Performance is not Influenced by a 5-HT Reuptake InhibitorInternational Journal of Sports Medicine, 2001
- The Corticosteroid Receptor Hypothesis of DepressionNeuropsychopharmacology, 2000
- Fluoxetine: A spectrum of clinical applications and postulates of underlying mechanismsNeuroscience & Biobehavioral Reviews, 1993
- The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulationProgress in Neuro-Psychopharmacology and Biological Psychiatry, 1988